Academic-industry relations
The topic is important and relates of course to concerns about the relationship between sponsorship and reported research results. This issue can be argued from many angles. To go directly to the point: good research cannot be conducted without support and federal funding increasingly goes to bench research, leaving a gap at the clinical investigation level. Industry, as well as special interest groups (clinical disorder societies for example) can and do fill this gap to an important extent. There is good reason for caution in the case of targeted research funding and peer-reviewed journal editors are well aware of this. However, as Dr. Hudson explains in the instance under discussion, the research in question is not targeted, i.e., the funding is not tied to any particular line of investigation. On the contrary, the funding is put in a pool and then, from this, is available to any applicant who successfully competes for an award. There is no link between the funding source, and the individual project and its parent department. This contrasts so clearly with the problems that may arise in the case of clinical trials of a new pharmaceutical product, where the relationship is quite different and all sides then benefit only after close scrutiny as to possible bias.
One can only conjecture as to motive on the part of companies responsible to their shareholders for funding research not tied in any way to their products. I would argue that it is reasonable for industry to participate in this funding because the maintenance of a viable national clinical research environment of high quality is a necessary part of their Research and Development picture. They have nowhere else to turn for this and, in the case of our specialty, the Canadian Anesthesia Research Foundation is therefore fulfilling a mutual interest in an admirable way. I do not recommend holding one's breath pending increased federal funding for clinical research.
Dr. Hudson's explanation exonerates university departments. The policy of the Journal as to the extent and manner in which it advertises its relationship to industry is, I believe, a separate and small part of a larger and more worrisome picture: industry product-promotion practices and the professional purchase choices of individual society members. It would be nice to see this confined to the paid advertisement pages in the case of the Journal. 
Potential pitfalls of interim analysis
To the Editor: In the evaluation of medical treatments, randomized trials are the current gold standard. According to the Mayo Clinic Clinical Trials glossary, 1 randomization minimizes the differences among groups by equally distributing people with particular characteristics to the trial arms. The goal of randomization is to minimize bias in the study design. We write to report the results of our randomization efforts that were identified during an interim analysis of a recent study conducted at our institution. This study assesses the effect of an oral cannabinoid on nausea scores, the incidence of vomiting and pain scores after gynecologic laparoscopy.
With the cooperation of the drug's manufacturer, we obtained 120 tablets of study medication and 120 placebo tablets that were indistinguishable. Each patient was to receive two pills, with the intention to study 60 treatment patients and 60 control patients. The pills were separated into pre-numbered plastic bags, two identical pills in each. A nurse not involved in data collection then selected individual bags at her discretion containing either study medication or placebo, and placed them into correspondingly numbered identical paper envelopes. The 120 envelopes were then mixed and placed in a plastic box. The code identifying the contents of each bag/envelope was stored on a sheet of paper, and filed in a sealed envelope. Envelopes were selected by one of the investigators on the day they were to be administered.
The protocol was designed for an interim analysis after study of approximately 40 patients. This was done to help ensure that patients in either the control or treatment group were not being put at risk unknowingly. After 42 patients were investigated the study was un-blinded. Much to our surprise, 37 of 42 patients received study medication and 5 received placebo.
The probability P of drawing 37 treatment and 5 placebo envelopes is given by the formula P = (combination of 37 treatments • combination of 5 placebos) ÷ combination of 42 total. 2 The formula for the possible number of combinations C is where r objects are taken from a total of n objects. Thus, the probability of drawing 37 treatment and five placebo envelopes is given by = 3.04 × 10 -10 . The probability of this combination is approximately three in 10 billion, which is extremely rare indeed! We reviewed the drug randomization and although selection of the envelopes was blinded, we cannot discount a systematic error in the envelope sorting process.
Our experience highlights one of the inherent hazards of interim analysis that manifests as an unequal number of patients in the study arms. Therefore, unanticipated risks in each study population may be difficult to determine at this point in the study. Moreover, marked skewing of the randomization process, as reported, may for all intents and purposes un-blind the remainder of the study. This experience demonstrates that although the randomization process will guarantee equal numbers in study groups after all patients are collected, interim analysis may be unwittingly affected by a biased distribution of subjects.
Editor's note
The important observations raised in this letter should be of interest to all clinical investigators and readers as well. There are several potential pitfalls relating to interim analyses, for which I have invited Dr. Peter Choi, the Journal's Consultant Epidemiologist, to address in the commentary which appears below.
Donald R. Miller MD, Editor-in-Chief
Commentary on "Potential pitfalls of interim analysis" The letter from Dr. Siddiqui et al. highlights several issues regarding the conduct of clinical trials. First, as the authors indicate, the probability of drawing 37 treatment and five placebo envelopes is extremely rare and suggests a systematic error in the generation of the allocation sequence. Although pre-numbered plastic bags were placed in the envelopes and mixed, the actual act of random allocation occurred with the selection of the envelopes. From this letter, we cannot
